Patterson Companies, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Patterson Companies, a leading supplier in the dental and animal health markets, has been acquired by Patient Square Capital, leading to Robert Rajalingam's appointment as the new CEO, effective April 17, 2025.
Patterson Companies, Inc. has completed its acquisition by Patient Square Capital, resulting in the company becoming a private entity and delisting from the NASDAQ.
Patterson Companies' shareholders have approved the acquisition of the company by Patient Square Capital at a special meeting held on April 1, 2025.
8-K: Patterson Companies Addresses Shareholder Lawsuits with Supplemental Proxy Statement Disclosures
Patterson Companies amends its proxy statement to address shareholder lawsuits alleging inadequate disclosures regarding its merger with Paradigm Parent, LLC, aiming to avoid delays and minimize legal expenses.
Patterson Companies' Q3 fiscal 2025 results reveal a decrease in net sales and earnings, impacted by market challenges and a cybersecurity attack, as the company progresses towards its acquisition by Patient Square Capital.
Patterson Companies announces the expiration of its go-shop period with no alternative acquisition proposals received, as the company moves forward with its $4.1 billion acquisition by Patient Square Capital, expected to close in April 2025.
Patterson Companies has agreed to be acquired by Patient Square Capital for $31.35 per share in cash, valuing the company at approximately $4.1 billion.
Patterson Companies' second quarter results show a slight increase in net sales but a decrease in earnings, impacted by a cybersecurity attack, and the company is now evaluating strategic alternatives.
Patterson Companies successfully held its annual shareholder meeting on September 16, 2024, electing all director nominees and approving executive compensation and auditor ratification proposals.
Patterson Companies' first quarter fiscal 2025 results were negatively impacted by a cybersecurity attack on Change Healthcare and lower sales in the animal health segment, leading to a decrease in net sales and earnings compared to the prior year.
Patterson Companies' fiscal 2024 fourth quarter saw a slight increase in net sales but a decrease in internal sales, impacted by a cybersecurity attack, while the company issued its fiscal 2025 earnings guidance.
Patterson Companies, Inc. announces the departure of Tim E. Rogan, President of Patterson Dental, effective immediately, with a transition agreement in place.
Patterson Companies has authorized a new $500 million share repurchase program and declared a quarterly cash dividend of $0.26 per share.
Patterson Companies' third quarter saw a slight increase in net sales, driven by dental consumables, but a decrease in net income, leading to a revised fiscal year earnings guidance.
Patterson Companies has elected Pamela Tomczik to its Board of Directors, effective February 2, 2024, to enhance the board's finance and strategy expertise.
Patterson Companies' Board of Directors has approved amendments to the company's bylaws, effective immediately, to reflect SEC universal proxy card rules and modernize governance practices.